DK2268669T3 - Bovin kolostrum omfattende antistoffer mod insulin til behandling af stofskifteforstyrrelsessygdomme - Google Patents

Bovin kolostrum omfattende antistoffer mod insulin til behandling af stofskifteforstyrrelsessygdomme

Info

Publication number
DK2268669T3
DK2268669T3 DK09720973.8T DK09720973T DK2268669T3 DK 2268669 T3 DK2268669 T3 DK 2268669T3 DK 09720973 T DK09720973 T DK 09720973T DK 2268669 T3 DK2268669 T3 DK 2268669T3
Authority
DK
Denmark
Prior art keywords
insulin
treatment
metabolic disorders
containing antibodies
bovine colostrum
Prior art date
Application number
DK09720973.8T
Other languages
English (en)
Inventor
Yaron Ilan
Gad Lalazar
Ami Ben-Yaakov
Tomer Adar
Original Assignee
Immuron Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immuron Ltd filed Critical Immuron Ltd
Application granted granted Critical
Publication of DK2268669T3 publication Critical patent/DK2268669T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK09720973.8T 2008-03-13 2009-03-11 Bovin kolostrum omfattende antistoffer mod insulin til behandling af stofskifteforstyrrelsessygdomme DK2268669T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3622708P 2008-03-13 2008-03-13
PCT/IL2009/000273 WO2009113065A1 (en) 2008-03-13 2009-03-11 Immuno-modulating compositions for the treatment of immune-mediated disorders

Publications (1)

Publication Number Publication Date
DK2268669T3 true DK2268669T3 (da) 2017-11-20

Family

ID=40875006

Family Applications (1)

Application Number Title Priority Date Filing Date
DK09720973.8T DK2268669T3 (da) 2008-03-13 2009-03-11 Bovin kolostrum omfattende antistoffer mod insulin til behandling af stofskifteforstyrrelsessygdomme

Country Status (7)

Country Link
US (2) US20110200610A1 (da)
EP (2) EP3231816A1 (da)
AU (1) AU2009222965B2 (da)
CA (1) CA2718381A1 (da)
DK (1) DK2268669T3 (da)
NZ (1) NZ587901A (da)
WO (1) WO2009113065A1 (da)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101785120B1 (ko) 2009-04-27 2017-10-12 이뮤론 리미티드 병적 장애의 치료 및/또는 예방에 이용되는 항-ｌｐｓ 풍부한 면역글로블린 조제물
DK2605791T3 (da) 2010-08-17 2017-06-19 Immuron Ltd Anti-lps-beriget immunoglobulinpræparat til anvendelse i behandling og/eller profylakse af en patologisk lidelse
KR102037885B1 (ko) 2010-11-23 2019-10-30 팬더릭스 인코포레이티드 광범위한, 미확인 또는 혼합된 임상적 적용에서 치료용 조성물들 및 방법들
IT1405998B1 (it) * 2010-12-09 2014-02-06 Bionest Ltd Gel polifunzionale contro la secchezza vaginale ad effetto diretto e ritardato
DE102011006809A1 (de) 2011-04-05 2012-10-11 Freistaat Bayern vertreten durch die Julius-Maximilians-Universität Würzburg Verwendung eines Mittels aus Antikörpern und/oder Insulin-like growth factor-Antagonisten
WO2013009843A1 (en) * 2011-07-11 2013-01-17 Camas Incorporated Compositions against bacterial toxins
ITMI20112435A1 (it) * 2011-12-30 2013-07-01 Bionest Ltd Profilassi e terapia delle malattie autoimmuni con citochine e fattori di crescita, antibatterici e anticorpi, isolati dai tessuti e dai liquidi biologici dei mammiferi
AU2013204801B2 (en) 2012-05-23 2014-11-06 Omniblend Innovation Pty Ltd Composition and method for management of diabetes or pre-diabetes
US10464998B2 (en) * 2013-10-30 2019-11-05 Hadasit Medical Research Services And Development Limited Anti-LPS enriched immunoglobulin for use in treatment and/or prophylaxis of fibrosis
BR112017018518A2 (pt) * 2015-04-17 2018-04-24 Ignova Gmbh biomarcadores previstos de resposta clínica para o tratamento de imunoglobulina antilps
US20190134096A1 (en) * 2016-05-06 2019-05-09 Hadasit Medical Research Services & Development Limited Hyperimmune colostrum in the modulation and treatment of conditions associated with the mammalian microbiome
CN111741762A (zh) * 2017-11-24 2020-10-02 防御素治疗学公司 使用防御素预防和治疗移植物抗宿主病
CN109010367A (zh) * 2018-08-21 2018-12-18 姜伟 牛初乳粉及其制备方法、制剂和在制备治疗肿瘤药物中的应用
US20220047646A1 (en) 2019-02-26 2022-02-17 Pantheryx, Inc. Compositions for management of disorders of the gastrointestinal tract
MX2022000424A (es) * 2019-07-09 2022-02-10 Aquero Canada Ltd Composiciones, procesos de produccion, esterilizacion y usos que promueven la salud de la leche liofilizada.
WO2022103871A1 (en) * 2020-11-10 2022-05-19 Wyomingv Immune, Inc. Therapeutic compositions for the treatment of covid-19

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1572220A (en) * 1976-10-07 1980-07-30 Mochida Pharm Co Ltd Immunochemical process of measuring physiologically active substances
US5980896A (en) 1989-06-30 1999-11-09 Bristol-Myers Squibb Company Antibodies reactive with human carcinomas
JP2879947B2 (ja) * 1990-06-04 1999-04-05 鐘紡株式会社 毛髪改質剤
US5369009A (en) * 1992-04-17 1994-11-29 Dana Farber Cancer Institute Antibodies for P-glycoprotein encoded by the mdr1 gene and uses thereof
CA2171607A1 (en) 1993-09-20 1995-03-30 Conor John Graham Method of obtaining immunoglobulins from colostrum and their use in pharmaceutical composition
US6436401B1 (en) * 1999-09-14 2002-08-20 Milkhaus Laboratory, Inc. Methods for alleviating symptoms associated with diabetes and diabetic neuropathy comprising administration of low levels of antibodies
WO2001087331A1 (fr) * 2000-05-19 2001-11-22 Sergey Georgievich Morozov Produits pharmaceutiques destines a la suppression de troubles auto-immuns au moyen de fragments liant les idiotypes des anticorps anti-idiotypiques
WO2002078742A2 (en) * 2001-01-30 2002-10-10 The Lauridsen Group, Incorporated Methods and compositions for treatment of immune dysfunction disorders
US20050175597A1 (en) 2002-03-21 2005-08-11 Rawlin Grant T. Compositions containing labile bioactive materials and mammalian colostrum, methods of preparation and treatment
CA2486801A1 (en) 2002-05-21 2003-11-27 Anadis Ltd Method of prophylaxis of infection
AU2003901008A0 (en) 2003-03-04 2003-03-20 Anadis Ltd Composition for the treatment and prevention of bacterial infections
EP1687066B1 (en) 2003-11-14 2012-08-29 Brigham and Women's Hospital, Inc. Methods of modulating immunity
CN101107013A (zh) 2004-11-22 2008-01-16 阿纳迪斯有限公司 生物活性组合物
US8071101B2 (en) * 2005-11-03 2011-12-06 Avaxia Biologics, Inc. Antibody therapy for treatment of diseases associated with gluten intolerance

Also Published As

Publication number Publication date
AU2009222965B2 (en) 2014-10-02
NZ587901A (en) 2012-11-30
WO2009113065A1 (en) 2009-09-17
AU2009222965A1 (en) 2009-09-17
EP3231816A1 (en) 2017-10-18
US20130164302A1 (en) 2013-06-27
CA2718381A1 (en) 2009-09-17
US20110200610A1 (en) 2011-08-18
EP2268669A1 (en) 2011-01-05
EP2268669B1 (en) 2017-10-18

Similar Documents

Publication Publication Date Title
DK2268669T3 (da) Bovin kolostrum omfattende antistoffer mod insulin til behandling af stofskifteforstyrrelsessygdomme
LTC2152290I2 (lt) Anti-il-5 antikūnų skyrimo būdai
DK3321276T3 (da) Fusionsproteiner til behandling af metaboliske lidelser
DK2269063T3 (da) Forudsigelse af risiko for større uønskede hjertehændelser
DK2643018T3 (da) Anti-il-6-antistoffer til behandling af oral mucositis
DK2262836T3 (da) Antistof mod CSF-1R
DK2114386T3 (da) Farmaceutisk sammensætning til behandling af diabeteskomplikationer
DK2776469T3 (da) Antistofmolekyler med specificitet for human ox40
DK2637690T3 (da) Flydende ANTI-TNF-alpha-antistofformuleringer med høj koncentration
PL2621923T3 (pl) Związki n-heteroarylu z mostkami cyklicznymi do leczenia chorób pasożytniczych
EA201400579A1 (ru) Антитела к il-36r
DK2504005T3 (da) Anvendelse af 1,3-diphenylprop-2-en-1-on-derivater til behandling af lever-sygdomme
DK3138854T3 (da) Antistoffer mod CD40
DK2177536T3 (da) Antistoffer mod amyloid-beta-peptid
BRPI0921022A2 (pt) tratamento com pirfenidona para pacientes com função hepática atípica
DK2220021T3 (da) Fremgangsmåde til fremstilling af terephtalsyre
DK2585088T3 (da) Sammensætning til forbedring af seksuel sundhed
EE201300007A (et) Kombineeritud ravimkoostis diabeedi ning ainevahetush„irete raviks
DK2734212T3 (da) Sammensætninger omfattende diclofenac til behandling af postoperativ smerte
DK3005986T3 (da) Infusion af lægemidler
SMT201500173B (it) Composizione utile per il trattamento di disturbi del metabolismo dei lipidi
DK2117525T3 (da) Anvendelse af 1-phenyl-3-dimethylamino-propanforbindelser til behandling af neuropatismerte
DK2552963T3 (da) Humaniserede antistoffer mod CXCR4 til behandling af cancer
BRPI1009783A2 (pt) compostos para o tratamento de distúrbios metabólicos.
DK2249866T3 (da) Anvendelse af et acetylsalicylsyresalt til behandlingen af virusinfektioner